CDKN2B-AS1 and osteosarcoma: The study of Lee et al. confirmed that lncRNA ANRIL can be used as a biomarker of chemosensitivity and prognosis of osteosarcoma, and downregulating the expression of ANRIL may be a therapeutic strategy to overcome the current standard treatment resistance [39].